Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease
Open Access
- 5 October 2026
- journal article
- review article
- Published by Wiley in JEADV Clinical Practice
Abstract
Background: Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives: To summarise the demographic, clinical, histopathological, management and disease course of SPD. Methods: A systematic review was conducted following PRISMA guidelines including all peer‐reviewed, English‐language studies reporting one or more SPD cases. Results: A total of 169 studies (17 case series, 152 case reports) and 205 patients were identified. The median age at diagnosis was 50 years, with a female‐to‐male ratio of 1.77:1. Over two‐thirds of patients had no comorbidities. Monoclonal gammopathy of unknown significance (MGUS) was the most common comorbidity (9.8%), followed by connective tissue disease (7.3%). Clinical pustules were observed in 92.3% of patients, most commonly affecting the trunk (75.1%), limbs (62%), axilla (44.4%) and groin (36.1%). Pruritus was the most common symptom (44.9%), with pain, burning, or irritation occurring in 16.3%. The median time to diagnosis in cases presenting with rash only was 3 years. A precipitant was identified in 22.9% of cases, including infections, flare of underlying condition, or medications such as calcium channel blockers, TNF‐α inhibitors, and antibiotics. In patients who had histopathological findings reported, subcorneal pustules and perivascular infiltrate most common. Dapsone was the most frequently used treatment (133/189, 70.4%), achieving complete response in 33.8%. Topical and systemic corticosteroids achieved complete responses in 22.5% and 29.6%, respectively. Biologics, mostly TNF‐α inhibitors, were used in 11.6%, with complete and partial responses in 63.6% and 27.3%. Limitations: The review's findings are limited by a limited sample size of heterogeneous, observational data, which can be prone to publication bias, so conclusions on SPD's clinical features and treatment efficacy should be interpreted cautiously pending larger, controlled studies. Conclusions: SPD remains a diagnostic and therapeutic challenge, with frequent delays and limited effectiveness of current treatments. These findings underscore the urgent need for prospective studies and targeted therapies to improve outcomes in this rare dermatosis. Systematic Review Registration: PROSPERO CRD42022344461.Keywords
This publication has 50 references indexed in Scilit:
- Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and TreatmentDermatology and Therapy, 2023
- A comprehensive insight into the anti-inflammatory properties of dapsoneNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- Spectrum of Antibiotic Activity and Its Relevance to the MicrobiomeJAMA Network Open, 2021
- Particulate matter 2.5 damages skin cells by inducing oxidative stress, subcellular organelle dysfunction, and apoptosisArchives of Toxicology, 2018
- Subcorneal Pustular Dermatosis: A Review of 30 Years of ProgressAmerican Journal of Clinical Dermatology, 2016
- Dapsone in dermatology and beyondArchives of Dermatological Research, 2013
- Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosisJournal of the American Academy of Dermatology, 1991
- Acute Generalized Exanthematous PustulosisArchives of Dermatology, 1991
- Subcorneal Pustular Dermatosis and Pustular PsoriasisArchives of Dermatology, 1983
- Dapsone-Induced Motor PolyneuropathyArchives of Dermatology, 1976